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Abstract A new monoclonal antibody recognizing
CEACAM6, which we named AP11, was generated by immu-
nizing BALB/c mice with phytohemagglutinin-activated hu-
man peripheral blood mononuclear cells. This study aims to
evaluate whether CEACAM6 can serve as a tumor marker
using AP11. We examined the expression of CEACAM6 with
AP11 in 11 human carcinoma cell lines by flow cytometry and
439 human tissues including 282 tumor tissues and 157 normal
tissues by immunohistochemistry. CEACAM6 epitope recog-
nized by AP11 was well preserved in formalin-fixed and
paraffin-embedded tissues. Adenocarcinomas of the stomach
(86%), colorectum (95%), pancreas (100%), and lung (83%),
urinary bladder (100 %), and mucinous ovarian tumors (88 %)
had a high rate of CEACAM6 immunoreactivity. We observed
a variable expression of CEACAM6 in hepatocellular
carcinomas (35 %), squamous cell carcinomas of the lung
(60 %), renal cell carcinomas (14 %), urothelial carcinomas
(13 %), serous carcinomas of the ovary (17 %), and breast
carcinomas (11 %). Small-cell carcinomas of the lung, prostatic
adenocarcinomas, papillary thyroid carcinomas, malignant
melanomas, giant cell tumors, and osteosarcomas were nega-
tive for CEACAM6. All normal tissues of various organs were
negative for CEACAM6. In conclusion, CEACAM6 as detect-
ed by AP11, may serve as a marker for mucin-producing
adenocarcinomas of the gastrointestinal tract and ovary as well
as non-small cell lung cancer. Thus, AP11 represents a valuable
diagnostic tool for detecting CEACMA6-positive cancers.
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Introduction
The carcinoembryonic antigen (CEA) gene family belongs to
the immunoglobulin superfamily [1] and comprises of 29 genes
that are located closely together on the long arm of chromo-
some 19 [2]. CEA (CD66e and CEACAM5) is a complex,
highly glycosylated macromolecule. It was first described in
1965 as a gastrointestinal oncofetal protein that is expressed
during fetal life but not in healthy adults, re-emerging in cancer
[3]. It is now accepted that this original description does not
apply to CEA. Although CEA is overexpressed in a majority of
carcinomas, including those of the gastrointestinal, respiratory,
and genitourinary tracts as well as in breast cancers, it is also
expressed in normal adult tissue [4]. Among the main proteins
of the CEA family, CEA is the only one that has been charac-
terized as a useful tumor marker in cancer patients. Increased
CEA levels are the first indicator of recurrent disease [5, 6], and
serum CEA levels are also used as a prognostic indicator in
colorectal cancer patients.
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CEACAM6 (CD66c, NCA-90) is a member of the CEA
family. It is expressed on granulocytes and on the epithelium of
various organs [7]. CEACAM6 is also expressed in many
human cancers and is observed in the sera of cancer patients
[4, 8–10]. Although CEACAM6 belongs to CEA family, the
levels of CEACAM6 do not correlate with the expression of
CEA [10]. CEACAM6 expression in colorectal cancer inverse-
ly correlates with cellular differentiation [11] and is an inde-
pendent prognostic factor associated with a higher risk of
colorectal cancer relapse [12]. CEACAM6 exhibits homotypic
binding with other members of the CEA family and heterotypic
interactions with integrin receptors [13]. CEACAM6 has been
shown to play a role in cell adhesion, invasion, and metastasis.
Antibodies that target the N-domain of CEACAM6 interfere
with cell-cell interactions [14]. The apoptotic response in nor-
mal cells to inadequate or inappropriate intercellular or matrix
attachment is termed anoikis [15]. While anoikis is thought to
maintain tissue order within multisystem organisms by
preventing ectopic cellular proliferation, resistance to anoikis
is a characteristic of tumor cells and has been reported to
contribute to primary tumorigenesis and metastasis in a number
of cancers [16–18]. CEACAM6 overexpression markedly in-
hibits anoikis [19]. CEACAM6 gene silencing by small inter-
fering RNA increases susceptibility to caspase-mediated
anoikis, decreases Akt phosphorylation under anchorage-
independent growth conditions, and inhibits metastatic poten-
tial [20]. Overexpression of CEACAM6 is also associated with
enhanced Src-dependent cellular invasion [21].
A variety of tumor markers is widely used to detect early
cancers and recurrence or metastasis after curative management
for many types ofmalignancies. Themetastatic process consists
of a series of sequential steps [22]. Eradication of metastatic
disease is critical for achieving survival in most cancer patients.
A relatively high rate of CEACAM6-positive reactivity has
been demonstrated in the sera of patients with lung cancer,
hepatocellular carcinoma, pancreatic cancer, breast cancer,
and colorectal cancer [10]. It has also been demonstrated that
the expression levels of CEACAM6 are higher than those of
CEA in malignant tumors including breast cancer, lung cancer,
prostate cancer, colon cancer, pancreatic cancer, and ovarian
cancer. Moreover, the level of CEACAM6 in liver metastases
of colon cancers was higher than in many corresponding pri-
mary tumors [23]. Thus, CEACAM6 may be more effective
than CEA as a marker for detecting early cancers and cancer
relapse or metastasis. CEACAM6 has also been shown to be
involved in the metastatic process and therefore it represents a
potential therapeutic target for the control of metastasis.
We generated a new monoclonal antibody (mAb) AP11,
which recognizes human CEACAM6. We used AP11 to an-
alyze CEACAM6 expression by immunohistochemistry in
282 human tumor tissues. The goals of the current study were
to (1) demonstrate the use of paraffin-embedded tissue blocks
and cell lines to confirm the expression pattern of AP11-
reactive CEACAM6 in different types of solid tumors, and
(2) develop evidence that supports the utility of CEACAM6 as
a tumor marker.
Materials and methods
Production of monoclonal antibody
Six week-old BALB/c mice were immunized intraperitoneally
with 107 phytohemagglutinin (PHA)-activated human periph-
eral blood mononuclear cells (PBMCs) at 2-week intervals for
2 months. Spleens were removed, and 108 spleen cells were
fused with 107 SP2/0-Ag14 mouse myeloma cells using poly-
ethylene glycol (PEG 4000, Rathway, NL, USA). The cell
hybrids were cultured in flat-bottom microculture trays at
37 °C in an atmosphere of humidified air containing 5 %
CO2, in hypoxanthine-aminopterin-thymidine (HAT) selec-
tion media (Sigma-Aldrich, USA). After 10 days, culture
supernatants were harvested and tested for reactivity to human
granulocytes by indirect immunofluorescence and flow cy-
tometry (Coulter, USA). One of the resulting hybridoma
clones whose supernatants were reactive to human
granulocytes was named AP11. AP11 was subcloned by lim-
iting dilution, and the culture supernatants of the sub-clones
were tested for antibody production.
Cloning of CEACAM6-hFc
Deletion mutants of CEACAM6 cDNA were derived from
human lung adenocarcinoma cell line A549 by RT-PCR and
ligated into pGEM-T vector (Promega, USA). The CEACAM6
cDNA was inserted into the mammalian expression vector
pcDNA3.1 using restriction endonucleases EcoRI. The
CEACAM6 cDNA fragment and human Fc cDNA were
inserted into the mammalian secretion vector pSecTag
(Invitrogen, USA) using HindIII, EcoRV, and XhoI. A day
before transfection, 293T cells were cultured and maintained
at 1×106 cells/mL density on six-well plates with 3mLDMEM
medium containing 10 % heat-inactivated fetal bovine serum
(FBS; GIBCO, Invitrogen, USA), incubated at 37 °C with 5 %
CO2. The dishes were 80 % confluent on the day of transfec-
tion. Deletion mutants of CEACAM6 in pSecTag vector were
transiently transfected into 293T cell by using Effectene trans-
fection reagent kit (QIAGEN, Germany). Three days later, the
resulting supernatant was tested by ELISA assay.
ELISA method
Deletion mutants of CEACAM6 recombinant protein were
tested for reactivity against AP11, goat anti-human Fc frag-
ment, and human immunoglobulin by ELISA. Microtitration
plates (96-well, Maxisorp; Nunc, Denmark) were coated with
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100 ng/well of goat anti-human Fc fragment in 1× phosphate-
buffered saline (PBS) and incubated with culture supernatant
for 1 h at 37 °C, followed by three washes. Next, the plates
were treated with the CEACAM6 recombinant protein super-
natant (100 μL) and the recombinant proteins of other
CEACAM families for 1 h at 37 °C, washed three times and
then treated with anti CEACAM6-horseradish peroxidase
(HRP) for 30 min at 37 °C. Following three washes, the plate
was incubated with 50 mL/well TMB (3, 3′, 5, 5′-
tetramethylbenzidine) substrate solution (Sigma-Aldrich,
USA) for 10 min at room temperature. Substrate development
was stopped by the addition of 2 N sulfuric acid, and the
absorbance was measured at 450 nm using an ELISA reader
(SpectraMax M5, Molecular devices, USA).
Western blot analysis
Peripheral blood neutrophils from healthy donors were lysed
in lysis buffer (1%NP-40 in 50mMTris-HCl, pH 7.4, 50mM
EDTA, and 1 mM PMSF). After centrifugation to remove cell
debris, the supernatant was subjected to 8 % SDS-PAGE
under non-reducing condition with appropriate molecular
weight markers. After electrophoretic transfer of the proteins
to nitrocellulose membrane, the membrane was blocked with
5 % skim milk in Tris-buffered saline (10 mM Tris-HCl,
150 mM NaCl, pH 7.6) containing 0.05 % Tween-20. The
membrane was incubated with AP11, followed by peroxidase-
conjugated goat anti-mouse IgG (Sigma, Saint Louis, 1:5000
dilution in blocking solution). Immunoreactive proteins were
visualized using the ECL chemoluminescence detection sys-
tem (Amersham Pharmaciam, Sweden).
Tissue samples and immunohistochemical staining
This study was approved by the ethics committee of
Chungbuk National University. Written informed consent
was obtained from the patients and patients’ families before
the beginning of the study. Tissue samples from 282 human
malignant tumors to 157 normal tissues were obtained from
the surgical pathology files of Chungbuk National University
Hospital and Korean Cancer Center as listed in Table 1. All
tissues had been fixed in 10 % formalin and embedded in
paraffin. Antigen retrieval was performed by microwave
heating in 10 mM sodium citrate, pH 6.0 (Dako, Denmark)
for 15 min. Indirect immunoperoxidase method was used.
The sections were incubated overnight with primary mAb
(AP11, 1:1000) in blocking buffer (4 % skim milk, 0.1 %
Tween-20 in 1× PBS) at 4 °C. On the next day, the sections
were washed and incubated with biotinylated goat anti-mouse
IgG and HRP-conjugated streptavidin (Dako, Denmark) for
20 min at room temperature. 3,3′-Diaminobenzidine (Sigma,
Saint Louis, USA) was used as chromogen. The pattern of
reactivity was analyzed based on serial hematoxylin-eosin-
stained sections. CEACAM6 expression detected by AP11
was defined as positive when staining was observed along
the luminal cell border or in the cytoplasm in ≥10% of cells in
the whole tissue section.
Results
Characterization of the AP11 target antigen
When the peripheral blood cells were analyzed by flow cy-
tometry using AP11, granulocytes exhibited a high level of
reactivity to AP11, indicating the expression of AP11 antigen,
whereas lymphocytes and monocytes were negative for AP11











Pancreatic (adenocarcinoma) 2 2
Liver (hepatocellular carcinoma) 17 10
Lung 58 30
Adenocarcinoma 18
Squamous cell carcinoma 20





Clear cell carcinoma 1




Prostate (adenocarcinoma) 8 8
Urethra (adenocarcinoma) 1 1
Breast (invasive ductal carcinoma) 9 9
Thyroid (papillary carcinoma) 8 8
Skin (melanoma) 4 4
Bone 37 20
Osteosarcoma 32
Giant cell tumor 5
Total 282 157
N number of samples examined
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(Fig. 1). Using Western blot with neutrophil lysates, the mo-
lecular weight of the AP11 antigen was shown to be approx-
imately 90 kDa (Fig. 2). Enzyme-based immunoassay deter-
mined the isotype of AP11 to be IgM. In a separate experiment
involving flow cytometric analysis, AP11was confirmed to be
highly specific to CEACAM6 (CD66c) not to cross-react with
CD66b (Fig. 3).
Epitope mapping of mAb AP11
Human CEACAM6 consists of an extracellular domain
(ECD) containing one N-terminal V-type Ig-like domain and
two C2-type Ig-like domains, and a hydrophobic C-terminal
propeptide. The GPI membrane anchor is attached at the C-
terminus following cleavage of the propeptide [24]. To iden-
tify the epitope for human CEACAM6 recombinant protein
that binds to AP11, epitope mapping was performed using
human Fc fusion protein gene constructs encoding
CEACAM6 deletion mutants (Fig. 4a). Sandwich ELISA
results showed that AP11 successfully recognized full-length
protein and BI/BamHI/lig protein, whereas HKP/HindIII/pstI/
lig protein was not recognized by AP11 (Fig. 4b). These
results revealed that the AP11 epitope is located in the func-
tional N-domain of CEACAM6.When ELISAwas performed
to analyze the cross-reactivity of AP11 with members of the
CEACAM family, AP11 was found to be reactive only with
CEACAM6 fusion protein, indicating specificity of AP11 for
CEACAM6 (Fig. 4c).
CEACAM6 expression in various tumor and normal tissues
Of the gastric adenocarcinomas, 24 of 28 (86 %) showed
CEACAM6 expression (Fig. 5a). In contrast, none of the
cases of dysplasia including both high- and low-grade lesions
expressed CEACAM6. These results suggest that AP11
Fig. 1 In-flow cytometric
analysis of peripheral blood using
mAb AP11. Granulocytes show a
high level of reactivity to mAb
AP11. Granulocytes (c) were
gated to determine the CD13 and
AP11 positivity (upper right
panel). Lower panels show
fluorescence for AP11 for
lymphocytes (a), monocytes (b),
and granulocytes, respectively
Fig. 2 Western blot analysis demonstrating that AP11 antigen detects a
protein of approximately 90 kDa in neutrophil lysates
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differentiates between gastric cancer and its premalignant
precursors.
Most colorectal adenocarcinomas (18 out of 19 cases)
were positive for CEACAM6 (Fig. 5b). Four of five
tubular adenomas (80 %) and four of five hyperplastic
polyps (80 %) stained positive for CEACAM6. In con-
trast to the stomach, most premalignant lesions were
also positive. Both cases of pancreatic adenocarcinoma
expressed CEACAM6 (Fig. 5c), whereas only 6 out of
17 hepatocellular carcinoma samples were CEACAM6
positive.
Overall, 47 % of the lung cancer samples showed
CEACAM6 expression. CEACAM6 was not expressed in
small cell lung cancer (SCLC) but in 71 % of non-small cell
lung cancer (NSCLC). Of the NSCLCs, lung adenocarci-
nomas more often showed CEACAM6 expression than squa-
mous cell carcinomas (Fig. 5d). This expression pattern sug-
gests that AP11 can effectively distinguish between NSCLCs
and SCLCs.
In ovarian cancers, CEACAM6 expression was highest in
mucinous carcinoma (seven out of eight samples, 88 %)
(Fig. 5e), whereas only 17 % of serous carcinoma samples
were positive for CEACAM6. None of the endometrioid and
clear cell cancers exhibited CEACAM6 expression.
Adenocarcinomas from the urinary bladder (Fig. 5f) and
urethra were CEACAM6 positive, whereas all prostate ade-
nocarcinomas were CEACAM6 negative. CEACAM6 was
expressed in a subset of clear renal cell carcinomas and
urothelial carcinomas (14 and 13 %, respectively).
Only one out of nine ductal carcinomas of the breast
showed CEACAM6 expression (Fig. 6a), whereas no papil-
lary thyroid carcinoma displayed CEACAM6 expression
(Fig. 6b). Of the 4 melanomas, 32 osteosarcomas, and 5 giant
cell tumors of the bone, none expressed CEACAM6 (Table 2).
None of normal tissue samples from the stomach,
colorectum, pancreas, liver, lung, breast, thyroid, ovary, kid-
ney, bladder, prostate, urethra, skin, and bone showed
CEACAM6 immunoreactivity.
Discussion
CEACAM6 ( CD6 6 c , NCA - 9 0 ) i s a 9 0 - kD a
glycosylphosphatidylinositol (GPI)-linked glycoprotein that
is overexpressed in a variety of gastrointestinal malignancies
[12, 25]. Despite lacking a transmembrane or intracellular
domain, CEACAM6 influences intracellular signal transduc-
tion and plays an important role in the progression of gastro-
intestinal cancer [8, 11, 25]. To date, pancreatic and colorectal
cancers have been the primary focus of CEACAM6 expres-
sion studies [8, 9, 12, 18–20, 25–28]. We show that
CEACAM6 is expressed in particular in mucin-producing,
gland-forming adenocarcinomas that arise in the gastrointes-
tinal tract, lung, and ovary. Blumenthal et al. explored the
expression of CEACAM6 and CEA in a panel of solid tumors,
including breast, lung, ovary, prostate, pancreas, and colorec-
tal cancers, using tissue microarrays [23]. Their results show
that CEACAM6 is more strongly expressed than CEA, and
that expression of CEACAM6 is strongly dependent on the
histologic tumor type. CEACAM6 expression in some sub-
types was 2–4-fold stronger than in normal tissue, while in
others, expression was similar to that in non-neoplastic tis-
sues. Adenocarcinomas of the lung expressed CEACAM6
more strongly than squamous cell carcinomas. CEACAM6
expression in large cell and poorly differentiated squamous
carcinomas was similar to non-neoplastic lung tissue, and
SCLC also expressed CEACAM6. We did not detect
CEACAM6 expression in SCLC, while adenocarcinomas
and squamous cell carcinomas frequently expressed
CEACAM6 (83 and 60 %, respectively). These findings point
Fig. 3 Flow cytometry result showing that AP11 is specific for
CEACAM6 and does not cross-react with CD66b in a CHO
transfection study. a CD66b transfection. b CEACAM6 transfection.
(N.C. negative control)
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indicate that AP11 stained CEACAM6 is a marker that differ-
entiates between SCLC and NSCLC in tissue samples.
CEACAM6 is highly expressed in ovarian mucinous neo-
plasms. Litkouhi et al. reported that CEACAM6 is expressed
Fig. 4 a Schematic diagram of recombinant CEACAM6-hFC fusion
genes. The constructs for CEACAM6-hFc fusion proteins deleted in the
extracellular domain were cloned to identify the AP11 epitope. b
Sandwich ELISA performed using goat anti-hFc specific antibody and
AP11 for the detection of various CEACAM6-hFc fusion proteins. The
results identified N-domain of CEACAM6 as the AP11-reactive epitope.
c ELISA results showing that AP11 only recognizes CEACAM6 among
families of hFc fusion proteins, when checked for cross-reactivity using
AP11 (y-axis, optical density)
Fig. 5 CEACAM6 immunoreactivity in a gastric adenocarcinoma, b colorectal adenocarcinoma, c pancreatic adenocarcinoma, d lung adenocarcinoma, e
ovarian mucinous carcinoma, and f urinary bladder adenocarcinoma. (Magnification, ×200)
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at higher levels in borderline mucinous neoplasms and inva-
sive mucinous carcinomas than in serous ovarian neoplasms
[29]. Consistent with this, we found that seven out of eight
mucinous carcinomas (88 %) but only one case of serous
carcinoma (17 %) stained positive for CEACAM6 using the
AP11 antibody. Taken together, these data suggest that
CEACMA6 may be a potential marker for mucinous ovarian
carcinomas.
Kinugasa et al. investigated CEACAM6 expression in
gastric adenocarcinoma and carcinoma cell lines in compari-
son to adjacent normal gastric mucosa using reverse
transcription-polymerase chain reaction (RT-PCR). They
found higher CEACAM6 transcript levels in gastric cancer
tissues compared to adjacent normal tissues, and CEACAM6
transcripts were detectable in 92 % (11/12) and 25% (3/12) of
gastric cancer and normal gastric mucosa samples, respective-
ly [30]. Yasui et al. demonstrated that CEACAM6 expression
is upregulated in gastric cancer compared to normal gastric
epithelia using serial analysis of gene expression (SAGE)
[31]. Kodera et al. showed similar upregulation of CEA and
CEACAM6 in gastric carcinomas using Northern blot analy-
sis [25]. We observed differential expression of the AP11-
reactive CEACAM6 epitope in invasive gastric cancer and
dysplastic lesions. We observed high expression (86 %) in
gastric cancer, which is consistent with previous reports, but
no or low CEACAM6 expression in dysplasia. Taken togeth-
er, these findings suggest that CEACAM6 is a potentially
useful marker for gastric cancer and differentiates between
carcinomas and gastric dysplasia.
Upregulation of CEACAM6 expression in hyperplastic
polyps and early adenomas indicates that it is an early event
in the development of colorectal cancer. Schozel et al. found
CEACAM6 expression in all 25 examined colonic polyps [8].
We observed expression of CEACMA6 in most tubular ade-
nomas (80 %) and hyperplastic polyps (80 %). A prognostic
significance of CEA expression for different types of carcino-
ma has not been established [32–35]. In contrast, expression
of CEACAM6 in colorectal cancer tissue is significantly
associated with poor prognosis [12]. Tissue expression of
CEACAM6 in liver metastases of colorectal cancer is higher
than that in primary colorectal cancer [23]. However, in breast,
colon, or lung carcinomas, CEACAM6 expression is similar
Table 2 Profile of CEACAM6-positive immunostaining in various
tumor tissues
Organ Diagnosis N (282) Positive N (%)
Stomach Adenocarcinoma 28 24 (86)
High-grade GED 5 0 (0)
Low-grade GED 5 0 (0)
Colorectum Adenocarcinoma 19 18 (95)
Tubular adenoma 5 4 (80)
Hyperplastic polyp 5 4 (80)
Pancreas Adenocarcinoma 2 2 (100)
Liver Hepatocellular carcinoma 17 6 (35)
Lung Adenocarcinoma 18 15 (83)
Squamous cell carcinoma 20 12 (60)
Small cell carcinoma 20 0 (0)
Ovary Mucinous carcinoma 8 7 (88)
Serous carcinoma 6 1 (17)
Endometrioid carcinoma 1 0 (0)
Clear cell carcinoma 1 0 (0)
Kidney Renal cell carcinoma 22 3 (14)
Bladder Urothelial carcinoma 30 4 (13)
Adenocarcinoma 3 3 (100)
Prostate Adenocarcinoma 8 0 (0)
Urethra Adenocarcinoma 1 1 (100)
Breast Invasive ductal carcinoma 9 1 (11)
Thyroid Papillary carcinoma 8 0 (0)
Skin Melanoma 4 0 (0)
Bone Osteosarcoma 32 0 (0)
Bone Giant cell tumor 5 0 (0)
GED gastric epithelial dysplasia, N number of samples examined
Fig. 6 CEACAM6 is not expressed in a invasive ductal carcinoma of breast and b papillary thyroid carcinoma. (Magnification, ×200)
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to that in their lymph node metastases [23]. CEACAM6 plays
an important role in migration, invasion, and adhesion, crucial
steps for the metastatic spread of cancer cells to secondary
tissue sites other than lymph nodes and potential targets for
new therapeutic modalities [36–38].
Pancreatic cancer has been the most extensively studied
neoplasm with respect to CEACAM6 expression [19–21, 23,
26–28]. The majority of invasive pancreatic adenocarcinomas
express CEACAM6, and CEACAM6-negative patients may
represent a subgroup of patients who survive longer after
surgical resection [28]. The level of CEACAM6 expression
influences the cellular invasiveness of pancreatic adenocarci-
nomas in a c-Src-dependent manner. Overexpression of
CEACAM6 enhances cellular invasion, whereas CEACAM6
knockdown attenuates invasiveness [21]. CEACAM6 is an
important determinant of malignant cellular behavior in pan-
creatic adenocarcinoma. Anoikis refers to the apoptotic re-
sponse induced in normal cells by inadequate or inappropriate
adhesion to a substrate [15]. It is postulated that resistance to
anoikis contributes to primary tumorigenesis and metastasis
[16–18]. Anoikis resistance is associated with increased
CEACAM6 expression, and CEACAM6 gene silencing im-
pairs anoikis resistance and inhibits the metastatic potential of
pancreatic adenocarcinoma cells in vivo [19]. CEACAM6
expression appears to be an early event in the progression to
pancreatic cancer. In a previous study, half of the low-grade
pancreatic intraepithelial neoplasia (PanIN) lesions examined
demonstrated some positive staining for CEACAM6, whereas
all PanIN3 lesions were CEACAM6 positive [28].
The expression of CEACAM6 in atypical ductal hyperpla-
sia of the breast (ADH) is strongly associated with the devel-
opment of invasive breast cancer and might serve as a marker
for its early diagnosis. It also represents a potential molecular
target for the treatment of patients with precancerous lesions
who express CEACAM6 to prevent the development of inva-
sive breast cancer [39]. In recent study, CEACAM6 was
reported as predictive for endocrine therapy resistance and a
unique mediator of migration and invasion of drug-resistant
estrogen-deprived breast cancer cells [40, 41].
The level of CEACAM6 in the blood of normal individuals
is higher (0.05 mg/L) than that of CEA (<2 μg/L). It is
therefore unlikely that CEACAM6 will be more useful than
CEA as a serum marker [4]. The expression of CEACAM6 in
solid tumors is higher than that of CEA, which makes it a
more promising target for antibody-based anti-metastatic and
chemosensitizing therapy [23].
In summary, we generated a new mAb, AP11, which
recognizes CEACAM6, and evaluated its ability to be used
as a tool to recognize CEACAM6 expression as a tumor
marker in human cancer cells and tissues. AP11 recognizes
CEACAM6 in formalin-fixed and paraffin-embedded tissues.
CEACAM6 expression is high in particular in mucin-produc-
ing, gland-forming adenocarcinomas arising in the
gastrointestinal tract, ovary, and NSCLCs. Thus, mAb
AP11-stained CEACAM6 may serve as a marker for mucin-
ous tumors.
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